US-based Epic Sciences, a biotech and cancer diagnostics company, raises $13m in Series B financing.
US-based Epic Sciences, a biotech and cancer diagnostics company, has raised $13m in Series B financing. The capital includes new investors Domain Associates, Roche Venture Fund, the corporate venturing unit of the Switzerland-based pharmaceutical company, and Pfizer Venture Investments, the corporate venturing unit of the US-based healthcare company. At the same time Kim Kamdar, a partner at Domain Associates, has joined its board.
The Californian company focuses on identifying and characterising rare cancers such as circulating tumour cells.
Kamdar said:…
